000			01145 a2200325 4500
005			20250513205912.0
264		0	_c20000424
008			200004s 0 0 eng d
022			_a0093-7754
040			_aNLM _beng _cNLM
100	1		_aMargolin, K A
245	0	0	_aInterleukin-2 in the treatment of renal cancer. _h[electronic resource]
260			_bSeminars in oncology _cApr 2000
300			_a194-203 p. _bdigital
500			_aPublication Type: Journal Article; Review
650	0	4	_aAntineoplastic Agents _xtherapeutic use
650	0	4	_aCarcinoma, Renal Cell _ximmunology
650	0	4	_aClinical Trials, Phase I as Topic
650	0	4	_aCombined Modality Therapy
650	0	4	_aDrug Administration Schedule
650	0	4	_aHumans
650	0	4	_aInterleukin-2 _xadministration & dosage
650	0	4	_aKidney Neoplasms _ximmunology
650	0	4	_aKiller Cells, Lymphokine-Activated _xdrug effects
650	0	4	_aNephrectomy
650	0	4	_aSignal Transduction _xdrug effects
650	0	4	_aSurvival Rate
650	0	4	_aThyroiditis, Autoimmune _xchemically induced
773	0		_tSeminars in oncology _gvol. 27 _gno. 2 _gp. 194-203
999			_c10721750 _d10721750